TLC C-53 data

LIPO presented positive data from a Phase II study at the Society of Critical Care Medicine meeting in San Francisco.

In the 25-patient trial, 13 of the 17 patients who received TLC C-53 had a statistically significant 25 percent or greater improvement in lung function or were removed from a ventilator at day eight, compared to 0 of 8 patients on placebo. By day eight, 9 of 17 patients on drug still required assisted ventilation, compared to all 8 placebo patients (p=0.03). ...